This company listing is no longer active
Eisai Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Belangrijke informatie
1.1%
Groei van de winst
1.0%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 6.0% |
Inkomstengroei | 5.1% |
Rendement op eigen vermogen | 3.6% |
Nettomarge | 4.3% |
Volgende winstupdate | 06 Feb 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Eisai geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 22 | 752,500 | 32,233 | 382,752 | 173,324 |
30 Jun 22 | 741,594 | 32,690 | 374,428 | 168,422 |
31 Mar 22 | 756,226 | 47,954 | 356,847 | 171,738 |
31 Dec 21 | 712,935 | 57,311 | 317,150 | 165,418 |
30 Sep 21 | 691,250 | 62,508 | 293,153 | 162,699 |
30 Jun 21 | 679,253 | 59,855 | 282,369 | 161,584 |
31 Mar 21 | 645,942 | 42,119 | 272,568 | 150,299 |
31 Dec 20 | 707,888 | 93,682 | 271,476 | 145,248 |
30 Sep 20 | 713,400 | 120,571 | 261,973 | 139,628 |
30 Jun 20 | 707,203 | 124,523 | 253,516 | 141,217 |
31 Mar 20 | 695,621 | 121,767 | 248,554 | 140,116 |
31 Dec 19 | 661,646 | 96,659 | 244,091 | 146,367 |
30 Sep 19 | 631,974 | 57,725 | 239,503 | 147,863 |
30 Jun 19 | 643,531 | 72,747 | 233,180 | 140,143 |
31 Mar 19 | 642,834 | 63,386 | 223,798 | 144,844 |
31 Dec 18 | 627,367 | 63,714 | 212,469 | 139,100 |
30 Sep 18 | 625,106 | 65,679 | 195,229 | 138,461 |
30 Jun 18 | 611,499 | 54,347 | 186,198 | 140,514 |
31 Mar 18 | 600,054 | 51,845 | 179,915 | 139,579 |
31 Dec 17 | 569,814 | 29,048 | 178,312 | 134,955 |
30 Sep 17 | 554,276 | 30,269 | 178,090 | 123,639 |
30 Jun 17 | 544,027 | 29,425 | 176,249 | 119,503 |
31 Mar 17 | 539,097 | 39,358 | 175,633 | 112,478 |
31 Dec 16 | 530,696 | 55,031 | 175,240 | 110,471 |
30 Sep 16 | 542,313 | 71,812 | 178,825 | 114,420 |
30 Jun 16 | 545,602 | 69,227 | 182,036 | 115,750 |
31 Mar 16 | 547,922 | 54,933 | 188,227 | 122,307 |
Kwaliteitswinsten: ESAL.Y has a large one-off gain of ¥13.4B impacting its September 30 2022 financial results.
Groeiende winstmarge: ESAL.Y's current net profit margins (4.3%) are lower than last year (9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ESAL.Y's earnings have grown by 1.1% per year over the past 5 years.
Versnelling van de groei: ESAL.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: ESAL.Y had negative earnings growth (-48.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7%).
Rendement op eigen vermogen
Hoge ROE: ESAL.Y's Return on Equity (3.6%) is considered low.